Skip to main content
. 2021 Sep 12;2021(9):CD011612. doi: 10.1002/14651858.CD011612.pub3

NCT01887990.

Study name Treatment of suicidal ideation with intravenous ketamine infusion
Methods Allocation: randomised
Endpoint classification: safety/efficacy study
Intervention model: parallel assignment
Masking: double‐blind (participant, caregiver, investigator, outcomes assessor)
Primary purpose: treatment
Participants Inclusion criteria
  • Age: 19‐64

  • Significant suicidality score on the Columbia Suicide Severity Rating Scale (C‐SSRS)

  • Willing and able to provide informed consent

  • Individuals with current substance abuse are allowed


Exclusion criteria
  • Pregnant or lactating; women of reproductive potential must have a negative urine pregnancy test (urine dipstick method)

  • Post‐partum state: defined as being within 2 months of delivery or miscarriage

  • Homicide risk as determined by clinical interview

  • Treatment with any medication known to specifically target the glutamate‐NMDA receptor system (i.e. lamotrigine, acamprosate, memantine, riluzole or lithium)

  • Any known hypersensitivity or serious adverse effect associated with ketamine treatment.

  • Any clinically significant medical condition or therapy that would preclude treatment with ketamine, to include recent myocardial infarction or unstable angina

  • Medically unstable, including acute withdrawal from alcohol or benzodiazepines requiring the use of benzodiazepine treatment.

  • Any of the following DSM‐IV diagnoses or categories:Any current psychosis or history of a non‐mood psychotic disorder (e.g., schizophrenia)Currently in a manic or mixed episodeCurrent use (defined by urine dipstick test) or abuse of hallucinogenic drugs (except marijuana) such as phencyclidineAny dissociative disorderAny pervasive developmental disorder (e.g., autism)A cognitive disorder (e.g., Alzheimer's Disease)Cluster A personality disorder (e.g., schizoid or schizotypal); note that cluster B and C personality disorders may be includedAny eating disorder

Interventions Ketamine versus saline
Outcomes Primary outcome measures: suicidality. Time frame: 2 weeks. [Designated as safety issue: Yes]. Scales and questionnaires Beck Scale for Suicidal Ideation
Starting date May 2012
Contact information mailto:rshelton%40uab.edu?subject=NCT01887990, F120307001, Treatment of Suicidal Ideation With Intravenous Ketamine Infusion
Notes NCT01887990